Listed by the USPTO as GOLLAMUDI, NEERAJA
Tech Center 3700 • Art Units: 2841 3783
This examiner grants 73% of resolved cases
This examiner is assigned to tech center 3700 and art unit 2841. The profile contains 179 resolved cases, with an allowance rate of 72.6% and a median of 1191 days to allowance. The interview lift is 40.0%, indicating a substantial positive association that may complement the favorable allowance baseline.
The listed companies are Insulet Corporation, Canon Inc., and Johnson & Johnson. The principal firms are Goodwin Procter LLP, MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, and Novel IP. Practitioners should plan for extended timing while using interviews selectively to address claim scope and other issues that may be resolved more effectively through direct discussion.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18821348 | MEDICAL SYSTEM | Non-Final OA | CANON KABUSHIKI KAISHA |
| 16720845 | INTRAVASCULAR DELIVERY SYSTEM WITH CENTRALIZED STEERING | Final Rejection | Evalve, Inc. |
| 17419406 | CONTINUOUS DOSING SYSTEMS AND APPROACHES | Final Rejection | AMGEN INC. |
| 16966391 | SYRINGE ASSEMBLY | Final Rejection | Becton, Dickinson and Company |
| 18804372 | SAFETY CONSTRAINTS FOR A CONTROL ALGORITHM BASED DRUG DELIVERY SYSTEM | Non-Final OA | INSULET CORPORATION |
| 18498275 | USE OF NON-INVASIVE GLUCOSE SENSORS AND GLUCOSE RATE OF CHANGE DATA IN AN INSULIN DELIVERY SYSTEM | Non-Final OA | INSULET CORPORATION |
| 17580249 | CONDUCTIVE ELEMENT IN ADHESIVE PATCH OF ON-BODY DRUG DELIVERY DEVICE FOR BODY CHANNEL COMMUNICATION | Final Rejection | Insulet Corporation |
| 17679265 | METHOD AND SYSTEM OF FULLY-AUTOMATED ARTIFICIAL PANCREAS CONTROL FOR COUNTERACTING POSTPRANDIAL HYPERGLYCEMIA | Non-Final OA | University of Virginia Patent Foundation |
| 18435702 | Injector Device | Final Rejection | Sanofi |
| 18950491 | Medicament Delivery Device | Non-Final OA | SHL Medical AG |
| 17653714 | Catheter Assembly with Stiffener | Final Rejection | MEDTRONIC VASCULAR, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy72.6% of resolved applications examined by Neeraja Gollamudi were allowed (179 resolved cases), compared with 85.1% across Art Unit 2841 over the last five years.
This examiner's interview lift is +40.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Neeraja Gollamudi took 1,191 days on average from filing to allowance.
Neeraja Gollamudi examines applications in Art Unit 2841 in Tech Center 3700 (Medical Devices & Mechanical Engineering).
